[4] Abingdon Health develops and manufactures tests on behalf of its contract customers and has produced and commercialised its own products.

[7] In 2015 Abingdon Health launched Seralite[8] a rapid diagnostic device for the quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in serum.

A range of tests designed to detect important and commercially damaging plant pathogens such as Phytophthora and Potato virus Y.

[10] At the start of the COVID-19 pandemic, Abingdon Health responded to the British government's 'call to arms' to produce a UK-made COVID-19 rapid antibody test.

Test development commenced in early 2020 with AbC-19 achieving CE marking for professional use across the United Kingdom and the European Union in July 2020.

[13] These one million tests were delivered in full in January 2021, but initially the Department of Health and Social Care (DHSC) refused to pay for them, citing the Judicial Review as one of the reasons for this.

Our position was clear: this was a straightforward purchase of goods/services by a public body from an established LFT provider on normal market terms.

"Mr Justice Waksman ruled in favour of the DHSC on all grounds, including lack of state aid to Abingdon Health and dismissed all claims brought by the GLP".